AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3357006 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC-M (CYC, 150 mg/m2 IM days 1 through 7; VCR, 2.0 mg/m2 IV day 8; ACT‐D, 1.7 mg/m2 IV day 8 every 21 days for four cycles)
Number of subjects: 70
Study 3357006 — intervention group
Group type: EXPERIMENTAL
Intervention: High, single-dose ACT‐D
Number of subjects: 70
Study 29388674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain self-management intervention plus nurse-led support
Number of subjects: 80
Study 29388674 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving electronic video modules only
Number of subjects: 80
Study 26873491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to antiretroviral therapy (ART)
Number of subjects: 105
Study 26873491 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict dose time instructions
Number of subjects: 105
Study 26873491 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancy between adherence to dose and dose schedule
Number of subjects: 105
Study 25717121 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound imaging screening before surgery, 1 day after surgery, and approximately 1 week after surgery.
Number of subjects: 100
Study 25717121 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasound imaging screening for control participants.
Number of subjects: 100
Study 25717121 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey administered to all participants after the scans.
Number of subjects: 100
Study 23537695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular taping with tension
Number of subjects: 23
Study 23537695 — intervention group
Group type: COMPARATOR
Intervention: Sham taping (tape applied without tension)
Number of subjects: 23
Study 23537695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Fibular taping and Sham taping)
Number of subjects: 23
Study 21134270 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized high intensity strength and interval training program plus usual care
Number of subjects: 120
Study 21134270 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 18207723 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted evidence-based intervention (Cape Town Women's Health CoOp)
Number of subjects: 112
Study 16340185 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavestinel
Number of subjects: 106
Study 16340185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 12788675 — intervention group
Group type: EXPERIMENTAL
Intervention: Real world scenario
Number of subjects: 200
Study 12788675 — intervention group
Group type: COMPARATOR
Intervention: Television episode scenario
Number of subjects: 200
Study 12788675 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher television viewing
Number of subjects: 200
Study 12788675 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing of dramas
Number of subjects: 200
Study 12788675 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving under the influence
Number of subjects: 200
Study 12788675 — intervention group
Group type: EXPERIMENTAL
Intervention: Passing out from drinking
Number of subjects: 200
Study 10867428 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 38
Study 10867428 — intervention group
Group type: COMPARATOR
Intervention: Drilling
Number of subjects: 38
Study 8630640 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg
Number of subjects: 51
Study 8630640 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg
Number of subjects: 51
Study 8630640 — intervention group
Group type: EXPERIMENTAL
Intervention: piroxicam 20 mg
Number of subjects: 51
Study 8630640 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study 7876657 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 96
Study 7876657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for alteplase)
Number of subjects: 96
Study 7876657 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3
Number of subjects: 96
Study 7876657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for c7E3)
Number of subjects: 96
Study 2466520 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically placed biliary endoprosthesis (10 French gauge)
Number of subjects: 52
Study 2466520 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical bypass
Number of subjects: 52
Study 2466520 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically placed biliary endoprosthesis
Number of subjects: 52
Study 2466520 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically placed biliary endoprosthesis and Conventional surgical bypass
Number of subjects: 52
Study 29609582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 times/week of 4×4 min AIT at 85‐95% peak heart rate (HRpeak)
Number of subjects: 465
Study 29609582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 times/week of 1×4 min AIT at 85‐95% HRpeak
Number of subjects: 465
Study 29609582 — intervention group
Group type: COMPARATOR
Intervention: 5‐7 times/week of ≥30 min MICT at 60‐70% HRpeak
Number of subjects: 465
Study 27307665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg) with ketamine (5 mg/kg) mixed in mango juice (Group MK)
Number of subjects: 36
Study 27307665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg/kg) and oral mango juice (Group DX)
Number of subjects: 36
Study 27307665 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline and oral mango juice (Group C)
Number of subjects: 36
Study 27307665 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MK
Number of subjects: 36
Study 26646670 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity interval training
Number of subjects: 0
Study 26646670 — intervention group
Group type: COMPARATOR
Intervention: Computer gaming skills training
Number of subjects: 0
Study 22901736 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 5mg
Number of subjects: 304
Study 22901736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 20584595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 μg (once daily)
Number of subjects: 234
Study 20584595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 μg (twice daily)
Number of subjects: 234
Study 20584595 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 200 μg (twice daily)
Number of subjects: 234
Study 20584595 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 375 μg (twice daily)
Number of subjects: 234
Study 20584595 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 500 μg (twice daily)
Number of subjects: 234
Study 19040374 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 12
Study 17256309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine lozenge (5 mg)
Number of subjects: 33
Study 17256309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine lozenge (3 mg)
Number of subjects: 33
Study 17256309 — intervention group
Group type: COMPARATOR
Intervention: Salagen tablet (control)
Number of subjects: 33
Study 17256309 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge (control)
Number of subjects: 33
Study 12729178 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretically constructed educational intervention
Number of subjects: 0
Study 10781472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (20 microg)
Number of subjects: 30
Study 10781472 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron (4 mg)
Number of subjects: 30
Study 8618581 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy (117 patients)
Number of subjects: 343
Study 8618581 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transplantation (115 patients)
Number of subjects: 343
Study 8618581 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized intensive chemotherapy (189 patients)
Number of subjects: 343
Study 8618581 — intervention group
Group type: EXPERIMENTAL
Intervention: Histocompatible bone marrow transplant from a sibling (contemporaneous group)
Number of subjects: 343
Study 8618581 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transplantation
Number of subjects: 343
Study 1621752 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 245
Study 1621752 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (500 mg three times daily)
Number of subjects: 245
Study 1621752 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily)
Number of subjects: 245
Study 6331150 — intervention group
Group type: COMPARATOR
Intervention: 17 g bran (B)
Number of subjects: 5
Study 6331150 — intervention group
Group type: COMPARATOR
Intervention: 18 g bran and fruit (BF)
Number of subjects: 5
Study 31614357 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐transecting bilayer substitution urethroplasty
Number of subjects: 21
Study 29798142 — intervention group
Group type: EXPERIMENTAL
Intervention: We‐Media management (Group A)
Number of subjects: 180
Study 29798142 — intervention group
Group type: COMPARATOR
Intervention: Telephone management (Group B)
Number of subjects: 180
Study 26282839 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning tobramycin dosing (0800 h)
Number of subjects: 18
Study 26282839 — intervention group
Group type: COMPARATOR
Intervention: Evening tobramycin dosing (2000 h)
Number of subjects: 18
Study 26282839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both morning and evening dosing
Number of subjects: 18
Study 24355995 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) using a cycle ergometer (n = 13)
Number of subjects: 43
Study 24355995 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (RT) using training machines (n = 14)
Number of subjects: 43
Study 24355995 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity sham training of the arms (C) (n = 16)
Number of subjects: 43
Study 23151126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (combined exercise and dietary advice)
Number of subjects: 12
Study 19597720 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-supplemented sportsmen group (group 1)
Number of subjects: 40
Study 19597720 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-supplemented sedentary group (group 3)
Number of subjects: 40
Study 19597720 — intervention group
Group type: COMPARATOR
Intervention: Sportsmen group without supplementation (group 2)
Number of subjects: 40
Study 19597720 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group without supplementation (group 4)
Number of subjects: 40
Study 17375732 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week couples group
Number of subjects: 257
Study 17375732 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week fathers group
Number of subjects: 257
Study 17375732 — intervention group
Group type: COMPARATOR
Intervention: Single-session control group
Number of subjects: 257
Study 16381265 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound instillation Group A1 (diclofenac IM)
Number of subjects: 100
Study 16381265 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound instillation Group A2 (diclofenac suppository)
Number of subjects: 100
Study 16381265 — intervention group
Group type: COMPARATOR
Intervention: Non-wound instillation Group B1 (diclofenac IM)
Number of subjects: 100
Study 16381265 — intervention group
Group type: COMPARATOR
Intervention: Non-wound instillation Group B2 (diclofenac suppository)
Number of subjects: 100
Study 16381265 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound instillation groups (A1, A2)
Number of subjects: 100
Study 16381265 — intervention group
Group type: COMPARATOR
Intervention: Non-wound instillation groups (B1, B2)
Number of subjects: 100
Study 12414865 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil diet (rich in monounsaturated fatty acids and alpha-linolenic acid)
Number of subjects: 55
Study 12414865 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil diet (rich in monounsaturated fatty acids)
Number of subjects: 55
Study 12414865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil diet (rich in n‐6‐polyunsaturated fatty acids)
Number of subjects: 55
Study 9526148 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 0
Study 9526148 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 0
Study 9324693 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 575
Study 9324693 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 575
Study 9324693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic agents (other patients)
Number of subjects: 575
Study 9324693 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete recanalization (TIMI 3)
Number of subjects: 575
Study 9324693 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent or incomplete recanalization (TIMI 0-2)
Number of subjects: 575
Study 9324693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction < 50%
Number of subjects: 575
Study 2692810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride (1.2-2.4 mg/day)
Number of subjects: 2
Study 2692810 — intervention group
Group type: COMPARATOR
Intervention: Lisuride (0.15 mg/day)
Number of subjects: 2
Study 90412 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized slide audiotape series on caries prophylaxis
Number of subjects: 200
Study 90412 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized slide audiotape series
Number of subjects: 200
Study 90412 — intervention group
Group type: COMPARATOR
Intervention: Simple verbal instruction
Number of subjects: 200
Study 31961490 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years® Autism Spectrum and Language Delays (IY‐ASLD) parent program delivered once a week for 12 weeks
Number of subjects: 58
Study 31961490 — intervention group
Group type: COMPARATOR
Intervention: Wait-list, treatment as usual control condition
Number of subjects: 58
Study 31961490 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory outcome analyses
Number of subjects: 58
Study 30458340 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 128
Study 30458340 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 128
Study 29099406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 97
Study 29099406 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Cognitive Therapy (NCT)
Number of subjects: 97
Study 29099406 — intervention group
Group type: COMPARATOR
Intervention: Intention-to-treat analysis
Number of subjects: 97
Study 25759095 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 10
Study 25759095 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 10
Study 24300609 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed, humidified CO2
Number of subjects: 150
Study 24300609 — intervention group
Group type: COMPARATOR
Intervention: Standard CO2 insufflation
Number of subjects: 150
Study 20728083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 600 μg
Number of subjects: 75
Study 20728083 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 μg
Number of subjects: 75
Study 20728083 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 75
Study 19637103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine/Stimulant use
Number of subjects: 214
Study 19637103 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use
Number of subjects: 214
Study 16713344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (exact dosage and duration not specified)
Number of subjects: 550
Study 15457381 — intervention group
Group type: EXPERIMENTAL
Intervention: AESOP 3000 robot system
Number of subjects: 240
Study 15457381 — intervention group
Group type: COMPARATOR
Intervention: Assistant group (control)
Number of subjects: 240
Study 15457381 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon subjective evaluation
Number of subjects: 240
Study 15457381 — intervention group
Group type: EXPERIMENTAL
Intervention: AESOP usage
Number of subjects: 240
Study 11304774 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated-intensified CEF (HD-CEF14) with G-CSF (cyclophosphamide 1,000 mg/m(2), epirubicin 80 mg/m(2), fluorouracil 600 mg/m(2), administered every 14 days)
Number of subjects: 151
Study 11304774 — intervention group
Group type: COMPARATOR
Intervention: Standard CEF (CEF21) (cyclophosphamide 600 mg/m(2), epirubicin 60 mg/m(2), fluorouracil 600 mg/m(2), administered every 21 days)
Number of subjects: 151
Study 9031302 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity viscoelastic (HVV)
Number of subjects: 74
Study 9031302 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity viscoelastic (LVV)
Number of subjects: 74
Study 9031302 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification (PHACO)
Number of subjects: 74
Study 9031302 — intervention group
Group type: COMPARATOR
Intervention: Manual nucleofragmentation (MNF)
Number of subjects: 74
Study 9031302 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular cataract extraction (ECCE)
Number of subjects: 74
Study 8290746 — intervention group
Group type: EXPERIMENTAL
Intervention: E2H9R9 regimen (9 months)
Number of subjects: 199
Study 8290746 — intervention group
Group type: EXPERIMENTAL
Intervention: Z2H9R9 regimen (9 months)
Number of subjects: 199
Study 8290746 — intervention group
Group type: EXPERIMENTAL
Intervention: Z2H6R6 regimen (6 months)
Number of subjects: 199
Study 3318902 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin 70 mg m‐2 i.v. 3‐weekly for 8 cycles (Regimen A)
Number of subjects: 48
Study 3318902 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin 35 mg m‐2 i.v. 3‐weekly for 16 courses (Regimen B)
Number of subjects: 48
Study 29160597 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training combined with psychosocial intervention
Number of subjects: 128
Study 29160597 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 128
Study 27323446 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (twice a week) and Acetylcysteine capsule (200 mg/time, t.i.d.) for 12 weeks
Number of subjects: 120
Study 27323446 — intervention group
Group type: COMPARATOR
Intervention: Acetylcysteine capsule (200 mg/time, t.i.d.) for 12 weeks
Number of subjects: 120
Study 25147155 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (n=28)
Number of subjects: 56
Study 25147155 — intervention group
Group type: COMPARATOR
Intervention: Control starch (n=28)
Number of subjects: 56
Study 22458987 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month collaborative care intervention (problem-solving therapy and/or pharmacotherapy, telephone symptom monitoring/relapse prevention, behavioral activation and patient navigation support)
Number of subjects: 193
Study 22458987 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 193
Study 20039955 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH)
Number of subjects: 219
Study 20039955 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic headache (EH)
Number of subjects: 219
Study 20039955 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 219
Study 20039955 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH) and episodic headache (EH)
Number of subjects: 219
Study 18930093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraderal TIV (0.1 ml injection, 9 microg HA/strain)
Number of subjects: 978
Study 18930093 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccine (0.5 ml injection, 15 microg HA/strain)
Number of subjects: 978
Study 17444098 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal topography-guided clear corneal tunnel phacoemulsification and IOL implantation
Number of subjects: 37
Study 17444098 — intervention group
Group type: COMPARATOR
Intervention: Conventional temporal corneal tunnel phacoemulsification and IOL implantation
Number of subjects: 37
Study 17444098 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal topography-guided clear corneal tunnel phacoemulsification
Number of subjects: 37
Study 17444098 — intervention group
Group type: COMPARATOR
Intervention: Conventional temporal corneal tunnel phacoemulsification
Number of subjects: 37
Study 14616872 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fat peanut challenge vehicle (22.9% fat)
Number of subjects: 4
Study 14616872 — intervention group
Group type: COMPARATOR
Intervention: Higher fat peanut challenge vehicle (31.5% fat)
Number of subjects: 4
Study 10758950 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829
Study 10758950 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829
Study 10758950 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) in patients with treated diabetes mellitus
Number of subjects: 1829
Study 10758950 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA) in patients with treated diabetes mellitus
Number of subjects: 1829
Study 10758950 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) in nondiabetic patients
Number of subjects: 1829
Study 10758950 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA) in nondiabetic patients
Number of subjects: 1829
Study 9162315 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of pulmonary tuberculosis
Number of subjects: 42
Study 9162315 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 42
Study 9162315 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with non granulomatous diseases)
Number of subjects: 42
Study 1564581 — intervention group
Group type: EXPERIMENTAL
Intervention: OH-CBL (computer-based learning program)
Number of subjects: 80